OPKO Health, Inc. (OPK) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-26

How it makes money

Patients pay for hormone and kidney treatments; the market success of NGENLA and Rayaldee drives the company's profit.

NGENLA is a weekly hormone injection for children with growth issues. Pfizer manages its commercialization, which drives its market reach.

Rayaldee is a treatment for kidney disease. Its revenue is driven by its adoption in the U.S. and international markets.

What protects it: the moat

Management claims that proprietary technology platforms protect the company's ability to develop new therapies.

It utilizes MSTAR technology to combine biological components into single molecules. It also uses peptide modification technology.

What growth costs

It must reinvest heavily in research and development to advance its pipeline of medical candidates.

The company incurs substantial expenses for research, development, and clinical trials. These costs are necessary to develop its biotechnology and pharmaceutical products.

What could damage it

If the company fails to commercialize its main drugs, it may never achieve profitability.

A failure to gain market acceptance or regulatory approval for Rayaldee or NGENLA would prevent the company from generating sufficient revenue.

About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Other companies in Diagnostics & Research